Cargando…

Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study

OBJECTIVE: COVID-19 due to SARS-CoV-2 virus is a new cause of severe acute respiratory syndrome (SARS). Little is known about the short-term cognitive prognosis for these patients. We prospectively evaluated basic cognitive functions shortly after care in the intensive care unit (ICU) and three mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Vialatte de Pémille, C., Ray, A., Michel, A., Stefano, F., Yim, T., Bruel, C., Zuber, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123423/
https://www.ncbi.nlm.nih.gov/pubmed/35610098
http://dx.doi.org/10.1016/j.neurol.2022.03.014
_version_ 1784711551936102400
author Vialatte de Pémille, C.
Ray, A.
Michel, A.
Stefano, F.
Yim, T.
Bruel, C.
Zuber, M.
author_facet Vialatte de Pémille, C.
Ray, A.
Michel, A.
Stefano, F.
Yim, T.
Bruel, C.
Zuber, M.
author_sort Vialatte de Pémille, C.
collection PubMed
description OBJECTIVE: COVID-19 due to SARS-CoV-2 virus is a new cause of severe acute respiratory syndrome (SARS). Little is known about the short-term cognitive prognosis for these patients. We prospectively evaluated basic cognitive functions shortly after care in the intensive care unit (ICU) and three months later in post-ICU COVID-19 patients. MATERIAL AND METHODS: We performed a prospective single-center study in our institution in Paris. Patients with SARS-CoV-2 SARS were prospectively recruited via our ICU. Patients were evaluated using standardized cognitive tests at baseline and at three months’ follow-up. Our primary endpoint was the evolution of the following five global tests: MMSE, FAB, oral naming test, Dubois five words test and MADRS. RESULTS: We explored 13 patients at baseline and follow-up. All patients had cognitive impairment at baseline but they all improved at three months, significantly on two of the five global tests after Bonferroni correction for multiple testing: MMSE (median 18 (IQR [15–22]) and 27 (IQR [27–29]) respectively, P = 0.002) and FAB test (median 14 (IQR [14–17]) and 17 (IQR [17,18]) respectively, P = 0.002). CONCLUSIONS: We report here the first longitudinal data on short-term cognitive impairment after intensive care in COVID-19 patients. We found acute and short-term cognitive impairment but significant improvement at three months. This pattern does not seem to differ from other causes of post-intensive care syndrome.
format Online
Article
Text
id pubmed-9123423
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-91234232022-05-21 Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study Vialatte de Pémille, C. Ray, A. Michel, A. Stefano, F. Yim, T. Bruel, C. Zuber, M. Rev Neurol (Paris) Original Article OBJECTIVE: COVID-19 due to SARS-CoV-2 virus is a new cause of severe acute respiratory syndrome (SARS). Little is known about the short-term cognitive prognosis for these patients. We prospectively evaluated basic cognitive functions shortly after care in the intensive care unit (ICU) and three months later in post-ICU COVID-19 patients. MATERIAL AND METHODS: We performed a prospective single-center study in our institution in Paris. Patients with SARS-CoV-2 SARS were prospectively recruited via our ICU. Patients were evaluated using standardized cognitive tests at baseline and at three months’ follow-up. Our primary endpoint was the evolution of the following five global tests: MMSE, FAB, oral naming test, Dubois five words test and MADRS. RESULTS: We explored 13 patients at baseline and follow-up. All patients had cognitive impairment at baseline but they all improved at three months, significantly on two of the five global tests after Bonferroni correction for multiple testing: MMSE (median 18 (IQR [15–22]) and 27 (IQR [27–29]) respectively, P = 0.002) and FAB test (median 14 (IQR [14–17]) and 17 (IQR [17,18]) respectively, P = 0.002). CONCLUSIONS: We report here the first longitudinal data on short-term cognitive impairment after intensive care in COVID-19 patients. We found acute and short-term cognitive impairment but significant improvement at three months. This pattern does not seem to differ from other causes of post-intensive care syndrome. Elsevier Masson SAS. 2022-10 2022-05-13 /pmc/articles/PMC9123423/ /pubmed/35610098 http://dx.doi.org/10.1016/j.neurol.2022.03.014 Text en © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Vialatte de Pémille, C.
Ray, A.
Michel, A.
Stefano, F.
Yim, T.
Bruel, C.
Zuber, M.
Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study
title Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study
title_full Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study
title_fullStr Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study
title_full_unstemmed Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study
title_short Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study
title_sort prevalence and prospective evaluation of cognitive dysfunctions after sars due to sars-cov-2 virus. the cognitivid study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123423/
https://www.ncbi.nlm.nih.gov/pubmed/35610098
http://dx.doi.org/10.1016/j.neurol.2022.03.014
work_keys_str_mv AT vialattedepemillec prevalenceandprospectiveevaluationofcognitivedysfunctionsaftersarsduetosarscov2virusthecognitividstudy
AT raya prevalenceandprospectiveevaluationofcognitivedysfunctionsaftersarsduetosarscov2virusthecognitividstudy
AT michela prevalenceandprospectiveevaluationofcognitivedysfunctionsaftersarsduetosarscov2virusthecognitividstudy
AT stefanof prevalenceandprospectiveevaluationofcognitivedysfunctionsaftersarsduetosarscov2virusthecognitividstudy
AT yimt prevalenceandprospectiveevaluationofcognitivedysfunctionsaftersarsduetosarscov2virusthecognitividstudy
AT bruelc prevalenceandprospectiveevaluationofcognitivedysfunctionsaftersarsduetosarscov2virusthecognitividstudy
AT zuberm prevalenceandprospectiveevaluationofcognitivedysfunctionsaftersarsduetosarscov2virusthecognitividstudy